As loss of chromosome 7 (−7/7q) that encodes CDK5 is a poor prognostic marker in myeloid malignancies, our results open the door to prioritize clinical evaluation of DHODHi in a challenging patient population for which there are currently limited therapeutic options (Honda et al, 2015). The gene discussed is CDK5; the disease is myeloid neoplasm.